SBI 087

Drug Profile

SBI 087

Alternative Names: PF-05230895; PF-5230895; SBI-087

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Emergent BioSolutions; Pfizer
  • Class Anti-inflammatories; Antirheumatics; Proteins
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 10 May 2012 Discontinued - Phase-II for Rheumatoid arthritis in Argentina (SC)
  • 10 May 2012 Discontinued - Phase-I for Rheumatoid arthritis in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top